Veradermics Stock Surges Nearly 500% Since February IPO as Bitcoin (BTC) Risk Appetite Broadens

First New Baldness Drugs in Nearly Three Decades

Wall Street has found its newest growth trade in an unlikely corner of consumer health: baldness. Three biotech firms are racing to deliver the first newly approved therapies for pattern hair loss in nearly three decades, and investors are positioning long before any regulator signs off. Veradermics (NYSE: MANE) has watched its stock climb almost 500% since its February initial public offering, making the hair-regrowth developer one of the year's most explosive listings. Its lead asset, an oral pill called VDPHL01, targets a condition that industry estimates place at roughly 50 million men and 30 million women in the United States. Absci (NASDAQ: ABSI) is testing an injection dosed two to three times over a six-month window; its shares have more than doubled so far this year. The dosing schedule matters commercially — two to three clinic visits per patient per half-year create recurring touchpoints that a daily pill or a topical cannot replicate. Cosmo Pharmaceuticals, the third contender, posted positive late-stage trial results for a topical solution but has traded far more cautiously against its US-listed peers. The opportunity is unusually clean: no newly approved drug for pattern hair loss has reached patients since the late 1990s, leaving care to depend on minoxidil and finasteride, two decades-old compounds tied to side effects that include heart palpitations and reduced sex drive. That status quo has persisted partly because baldness was long treated as cosmetic rather than medical, which deterred large-pharma investment. COINOTAG's review of the three programs shows none has cleared the approval stage yet, so every point of the rally rests on trial progress rather than product sales — and with only a handful of pure-plays available, a single data update re-prices the entire complex.

The GLP-1 Playbook Behind the Rally

The enthusiasm did not form in a vacuum, and the template is easy to identify. Eli Lilly's stock has risen nearly 350% over the past five years, a run driven largely by its GLP-1 weight-loss drugs Zepbound and Mounjaro — and that rally rewired investor appetite for consumer-facing healthcare biotech the same way earlier thematic waves lifted mega-cap platforms such as Meta Platforms. Lilly has since invested $40 million in Absci, betting that hair regrowth could follow a similar injectable playbook to obesity care. Geoff Hsu, a portfolio manager at OrbiMed's Biotech Growth Trust, has argued that obesity and hair loss share a defining trait — each is a massive consumer category, which is precisely why both can offer significant revenue potential. Weight-loss drugs first drove that shift, but the market has since shown it will underwrite any credible shot at a huge, self-pay consumer category. The comparison is doing heavy lifting here. Unlike established technology names, where investors can anchor on balance sheets the way they do with IBM, none of the three hair-loss developers has an approved product, and the earliest regulatory filings are not expected before 2027. Investors are, in effect, pricing demand years before any drug reaches a pharmacy shelf. The gap between Cosmo's careful trading and the US names' steeper moves suggests European-listed investors are applying a stricter discount to unproven late-stage data. If VDPHL01 or the Absci injection reads out cleanly, the addressable market could rival the early GLP-1 opportunity; if the trials stumble, the same concentration that fueled the rally would accelerate the drawdown. Readers tracking the market in real time can follow live spot and futures prices on Gate.

Risk Appetite Spills Into Crypto

Our read at COINOTAG: the same risk-seeking bid that turned GLP-1 into a multiyear trade is now hunting the next consumer-health shortage, and it sits alongside visible appetite in digital assets. Eli Lilly's five-year chart on TradingView — a gain of roughly 350% — remains the benchmark these stories are measured against. Bitcoin (BTC) changes hands near $77,500 at the time of writing, and sentiment meters such as the crypto fear and greed index show traders still paying today for demand that may take years to arrive — the same structure as a pre-revenue biotech position. Across speculative pockets from silver to crypto, until the 2027 filings land, positioning rather than pharmacology will keep setting the price.